Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Bain Capital Life Sciences Investors LLC

Bain Capital Life Sciences Investors LLC reduced its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 37.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,249,069 shares of the company’s stock after selling 3,200,679 shares during the period. Annexon makes up approximately 3.2% of Bain Capital Life Sciences Investors LLC’s holdings, making the stock its 9th biggest holding. Bain Capital Life Sciences Investors LLC owned 4.92% of Annexon worth $26,928,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. E Fund Management Co. Ltd. lifted its position in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock valued at $79,000 after acquiring an additional 4,086 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Annexon by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 268,166 shares of the company’s stock worth $1,376,000 after buying an additional 4,806 shares during the period. Rhumbline Advisers grew its holdings in shares of Annexon by 4.3% during the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company’s stock worth $728,000 after buying an additional 5,854 shares in the last quarter. Bank of New York Mellon Corp raised its position in Annexon by 2.8% in the 4th quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company’s stock valued at $1,183,000 after buying an additional 6,226 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Annexon by 17.7% in the 4th quarter. MetLife Investment Management LLC now owns 64,967 shares of the company’s stock valued at $333,000 after acquiring an additional 9,755 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Tuesday, March 4th.

Annexon Price Performance

Shares of NASDAQ ANNX opened at $1.46 on Monday. The business has a 50-day moving average of $2.28 and a 200-day moving average of $4.39. The stock has a market capitalization of $160.18 million, a price-to-earnings ratio of -1.39 and a beta of 1.24. Annexon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, sell-side analysts expect that Annexon, Inc. will post -0.96 EPS for the current year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.